CYP3A5 Gene

HGNC Family	Cytochrome P450s (CYP)
Name	cytochrome P450, family 3, subfamily A, polypeptide 5
Description	This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The encoded protein metabolizes drugs as well as the steroid hormones testosterone and progesterone. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Two pseudogenes of this gene have been identified within this cluster on chromosome 7. Expression of this gene is widely variable among populations, and a single nucleotide polymorphism that affects transcript splicing has been associated with susceptibility to hypertensions. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014]
Summary	{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n CYP3A5 is a polymorphic member of the CYP3A subfamily of drug‐metabolizing enzymes that is expressed mainly in the liver and intestine. Its function is defined by common genetic variants; for example, carriers of the functional CYP3A51 allele produce appreciable amounts of the enzyme, whereas individuals homozygous for the nonfunctional CYP3A53 allele express little or none. This differential expression has a direct impact on the metabolism and clearance of clinically important substrates. In transplant recipients, for instance, CYP3A5 expressors consistently require higher doses of tacrolimus to attain target blood concentrations compared with nonexpressors, reflecting increased metabolic clearance (["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "], ["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "], ["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "], ["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": "]). Moreover, CYP3A5 expression contributes significantly to the overall CYP3A‐mediated metabolic capacity, and induction studies have demonstrated that its promoter is activated by nuclear receptors such as PXR and CAR in an ER6‐dependent fashion, similar to CYP3A4 (["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": "]). Population studies have highlighted marked interethnic variability in CYP3A5 expression levels, with the functional allele occurring at different frequencies in distinct ethnic groups, thereby influencing interindividual differences in drug disposition (["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": "]). In addition, although CYP3A5 may not be a major determinant for the pharmacodynamics of every drug, its activity appears to influence the lipid‐lowering efficacy of certain statins—CYP3A5 expressors show a less robust decrease in cholesterol levels likely because of enhanced drug metabolism (["}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": "]). Overall, the functional variability of CYP3A5 plays a critical role in the clearance of several drugs with narrow therapeutic indices, making it a promising biomarker for personalized dosing strategies in clinical practice.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Dennis A Hesselink, Ron H N van Schaik, Ilse P van der Heiden, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Pharmacol Ther (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/S0009-9236(03)00168-1"}], "href": "https://doi.org/10.1016/S0009-9236(03"}, {"type": "t", "text": "00168-1) PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12966368"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12966368"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Vincent Haufroid, Michel Mourad, Valérie Van Kerckhove, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenetics (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/00008571-200403000-00002"}], "href": "https://doi.org/10.1097/00008571-200403000-00002"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15167702"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15167702"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Norihiko Tsuchiya, Shigeru Satoh, Hitoshi Tada, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Transplantation (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.tp.0000137789.58694.b4"}], "href": "https://doi.org/10.1097/01.tp.0000137789.58694.b4"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15502717"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15502717"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Iain A M Macphee, Salim Fredericks, Maha Mohamed, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Transplantation (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.tp.0000151766.73249.12"}], "href": "https://doi.org/10.1097/01.tp.0000151766.73249.12"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15729180"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15729180"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Oliver Burk, Ina Koch, Judy Raucy, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biol Chem (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1074/jbc.M404949200"}], "href": "https://doi.org/10.1074/jbc.M404949200"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15252010"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15252010"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "E Hustert, M Haberl, O Burk, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The genetic determinants of the CYP3A5 polymorphism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenetics (2001)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/00008571-200112000-00005"}], "href": "https://doi.org/10.1097/00008571-200112000-00005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "11740341"}], "href": "https://pubmed.ncbi.nlm.nih.gov/11740341"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Kari T Kivistö, Mikko Niemi, Elke Schaeffeler, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Lipid-lowering response to statins is affected by CYP3A5 polymorphism."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Pharmacogenetics (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1097/01.fpc.0000114762.78957.a5"}], "href": "https://doi.org/10.1097/01.fpc.0000114762.78957.a5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15284534"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15284534"}]}]}]}
Synonyms	CYPIIIA5, CP35, P450PCN3, PCN3
Proteins	CP3A5_HUMAN
NCBI Gene ID	1577
API
Download Associations
Predicted Functions
Co-expressed Genes
Expression in Tissues and Cell Lines

Functional Associations

CYP3A5 has 8,967 functional associations with biological entities spanning 8 categories (molecular profile, organism, chemical, functional term, phrase or reference, disease, phenotype or trait, structural feature, cell line, cell type or tissue, gene, protein or microRNA) extracted from 115 datasets.

Click the + buttons to view associations for CYP3A5 from the datasets below.

If available, associations are ranked by standardized value

Harmonizome 3.0

CYP3A5 Gene

Functional Associations

Please acknowledge the Harmonizome in your publications by citing the following reference(s):

	Dataset	Summary
	Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles	tissues with high or low expression of CYP3A5 gene relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset.
	Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles	tissue samples with high or low expression of CYP3A5 gene relative to other tissue samples from the Allen Brain Atlas Aging Dementia and Traumatic Brain Injury Tissue Sample Gene Expression Profiles dataset.
	Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray	tissue samples with high or low expression of CYP3A5 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by Microarray dataset.
	Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq	tissue samples with high or low expression of CYP3A5 gene relative to other tissue samples from the Allen Brain Atlas Developing Human Brain Tissue Gene Expression Profiles by RNA-seq dataset.
	Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles	tissues with high or low expression of CYP3A5 gene relative to other tissues from the Allen Brain Atlas Prenatal Human Brain Tissue Gene Expression Profiles dataset.
	BioGPS Cell Line Gene Expression Profiles	cell lines with high or low expression of CYP3A5 gene relative to other cell lines from the BioGPS Cell Line Gene Expression Profiles dataset.
	BioGPS Human Cell Type and Tissue Gene Expression Profiles	cell types and tissues with high or low expression of CYP3A5 gene relative to other cell types and tissues from the BioGPS Human Cell Type and Tissue Gene Expression Profiles dataset.
	BioGPS Mouse Cell Type and Tissue Gene Expression Profiles	cell types and tissues with high or low expression of CYP3A5 gene relative to other cell types and tissues from the BioGPS Mouse Cell Type and Tissue Gene Expression Profiles dataset.
	Carcinogenome Chemical Perturbation Carcinogenicity Signatures	small molecule perturbations changing expression of CYP3A5 gene from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.
	CCLE Cell Line Gene CNV Profiles	cell lines with high or low copy number of CYP3A5 gene relative to other cell lines from the CCLE Cell Line Gene CNV Profiles dataset.
	CCLE Cell Line Gene Expression Profiles	cell lines with high or low expression of CYP3A5 gene relative to other cell lines from the CCLE Cell Line Gene Expression Profiles dataset.
	CellMarker Gene-Cell Type Associations	cell types associated with CYP3A5 gene from the CellMarker Gene-Cell Type Associations dataset.
	ChEA Transcription Factor Binding Site Profiles	transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP3A5 gene from the CHEA Transcription Factor Binding Site Profiles dataset.
	ChEA Transcription Factor Targets	transcription factors binding the promoter of CYP3A5 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets dataset.
	ChEA Transcription Factor Targets 2022	transcription factors binding the promoter of CYP3A5 gene in low- or high-throughput transcription factor functional studies from the CHEA Transcription Factor Targets 2022 dataset.
	CM4AI KOLF21J CRISPRi Gene Perturbation Atlas	gene perturbations changing expression of CYP3A5 gene from the CM4AI KOLF21J CRISPRi Gene Perturbation Atlas dataset.
	CMAP Signatures of Differentially Expressed Genes for Small Molecules	small molecule perturbations changing expression of CYP3A5 gene from the CMAP Signatures of Differentially Expressed Genes for Small Molecules dataset.
	COMPARTMENTS Curated Protein Localization Evidence Scores	cellular components containing CYP3A5 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores dataset.
	COMPARTMENTS Curated Protein Localization Evidence Scores 2025	cellular components containing CYP3A5 protein from the COMPARTMENTS Curated Protein Localization Evidence Scores 2025 dataset.
	COMPARTMENTS Text-mining Protein Localization Evidence Scores	cellular components co-occuring with CYP3A5 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores dataset.
	COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025	cellular components co-occuring with CYP3A5 protein in abstracts of biomedical publications from the COMPARTMENTS Text-mining Protein Localization Evidence Scores 2025 dataset.
	COSMIC Cell Line Gene CNV Profiles	cell lines with high or low copy number of CYP3A5 gene relative to other cell lines from the COSMIC Cell Line Gene CNV Profiles dataset.
	COSMIC Cell Line Gene Mutation Profiles	cell lines with CYP3A5 gene mutations from the COSMIC Cell Line Gene Mutation Profiles dataset.
	CTD Gene-Chemical Interactions	chemicals interacting with CYP3A5 gene/protein from the curated CTD Gene-Chemical Interactions dataset.
	CTD Gene-Disease Associations	diseases associated with CYP3A5 gene/protein from the curated CTD Gene-Disease Associations dataset.
	DepMap CRISPR Gene Dependency	cell lines with fitness changed by CYP3A5 gene knockdown relative to other cell lines from the DepMap CRISPR Gene Dependency dataset.
	DGIdb Drug Targets 2026	interacting drugs for CYP3A5 protein from the DGIdb Drug Targets 2026 dataset.
	DISEASES Text-mining Gene-Disease Association Evidence Scores	diseases co-occuring with CYP3A5 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset.
	DISEASES Text-mining Gene-Disease Association Evidence Scores 2025	diseases co-occuring with CYP3A5 gene in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores 2025 dataset.
	DisGeNET Gene-Disease Associations	diseases associated with CYP3A5 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Disease Associations dataset.
	DisGeNET Gene-Phenotype Associations	phenotypes associated with CYP3A5 gene in GWAS and other genetic association datasets from the DisGeNET Gene-Phenoptype Associations dataset.
	DrugBank Drug Targets	interacting drugs for CYP3A5 protein from the curated DrugBank Drug Targets dataset.
	ENCODE Histone Modification Site Profiles	histone modification site profiles with high histone modification abundance at CYP3A5 gene from the ENCODE Histone Modification Site Profiles dataset.
	ENCODE Transcription Factor Binding Site Profiles	transcription factor binding site profiles with transcription factor binding evidence at the promoter of CYP3A5 gene from the ENCODE Transcription Factor Binding Site Profiles dataset.
	ENCODE Transcription Factor Targets	transcription factors binding the promoter of CYP3A5 gene in ChIP-seq datasets from the ENCODE Transcription Factor Targets dataset.
	ESCAPE Omics Signatures of Genes and Proteins for Stem Cells	PubMedIDs of publications reporting gene signatures containing CYP3A5 from the ESCAPE Omics Signatures of Genes and Proteins for Stem Cells dataset.
	GAD Gene-Disease Associations	diseases associated with CYP3A5 gene in GWAS and other genetic association datasets from the GAD Gene-Disease Associations dataset.
	GAD High Level Gene-Disease Associations	diseases associated with CYP3A5 gene in GWAS and other genetic association datasets from the GAD High Level Gene-Disease Associations dataset.
	GDSC Cell Line Gene Expression Profiles	cell lines with high or low expression of CYP3A5 gene relative to other cell lines from the GDSC Cell Line Gene Expression Profiles dataset.
	GeneRIF Biological Term Annotations	biological terms co-occuring with CYP3A5 gene in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.